Acorda Therapeutics Inc (NASDAQ:ACOR) Receives $19.44 Consensus Price Target from Brokerages
Acorda Therapeutics Inc (NASDAQ:ACOR) has been assigned a consensus rating of “Hold” from the fourteen research firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $19.44.
ACOR has been the subject of several research reports. BidaskClub downgraded Acorda Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 29th. Zacks Investment Research downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $18.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, May 7th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, March 19th.
Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can raised its stake in Acorda Therapeutics by 100.8% in the 4th quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,062 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Acorda Therapeutics in the 4th quarter valued at about $44,000. Financial Gravity Wealth Inc. acquired a new position in Acorda Therapeutics in the 1st quarter valued at about $44,000. NumerixS Investment Technologies Inc acquired a new position in Acorda Therapeutics in the 4th quarter valued at about $77,000. Finally, Piedmont Investment Advisors Inc. acquired a new position in Acorda Therapeutics in the 1st quarter valued at about $134,000.
Acorda Therapeutics (NASDAQ:ACOR) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.51. The company had revenue of $44.14 million for the quarter, compared to analyst estimates of $35.14 million. Acorda Therapeutics had a negative net margin of 1.40% and a positive return on equity of 9.34%. The business’s revenue was down 58.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.14 EPS. On average, sell-side analysts forecast that Acorda Therapeutics will post -4.11 earnings per share for the current fiscal year.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Recommended Story: What is a stock buyback?
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.